Premium
Immunomodulators in the treatment of cutaneous lymphoma
Author(s) -
Rogalski Christina,
Dummer Reinhard,
Burg Günter
Publication year - 1999
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.1999.tb00858.x
Subject(s) - medicine , thymopentin , extracorporeal photopheresis , lymphoma , monoclonal antibody , cutaneous lymphoma , cutaneous t cell lymphoma , immunology , dermatology , disease , mycosis fungoides , graft versus host disease , antibody
Background Cutaneous lymphoma involves clonal proliferation of immunocompetent cells. Immunointerventional strategies are a rational approach to the treatment of cutaneous lymphoma given the pathophysiological aspects of the disease. Objective Immunomodulatory therapies in cutaneous lymphoma are reviewed, including interferons, interleukin‐2, cyclosporin A, monoclonal antibodies, autologous bone marrow transplantation, fusion toxins, thymopentin and extracorporeal photopheresis as well as recently reported methods such as vaccination therapy, mycophenolate, and new retinoids. Results/Conclusion Cutaneous lymphoma is sensitive to immunointerventions. This approach should be used in early stages of the disease when it is more susceptible and benefits better from immunomodulatory treatment modalities.